A Phase I, Open Label, Dose Escalation Study of Oral Administration of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies.

Trial Profile

A Phase I, Open Label, Dose Escalation Study of Oral Administration of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Apr 2015

At a glance

  • Drugs Sapanisertib (Primary) ; Paclitaxel; Trastuzumab
  • Indications Advanced breast cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Millennium
  • Most Recent Events

    • 07 Apr 2015 Status changed from active, no longer recruiting to completed, according to to ClinicalTrials.gov record.
    • 15 Nov 2013 Planned end date changed from 1 Sep 2014 to 1 Feb 2014 as reported by ClinicalTrials.gov.
    • 15 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top